American Bio Medica Launches One of the Industry's Most Extensive National Collection Networks With Western Pathology Consultants
Business Wire - July 08, 1999 08:46
HUDSON, N.Y.--(BUSINESS WIRE)--July 8, 1999--American Bio Medica Corp. (NASDAQ: ABMC) today announced its affiliation with Western Pathology Consultants, Inc. (WPCI) to provide a total drug testing program that combines a national network of collection centers performing ABMC's Rapid Drug Screen(TM) with a broad range of value-added services.
ABMC and WPCI's national network is one of the largest in the drug testing industry. It presently includes 1,650 locations and 900 mobile collectors; the latter perform the Rapid Drug Screen on-site and are especially useful for random screening programs. An additional 2,000 centers are being brought on board over the next 6 to 9 months in order to further expand the network.
ABMC will now move forward with an aggressive sales and marketing program for high volume testers that, to date, have for the most part remained with laboratories and third-party administrators. The new national network affiliation between ABMC and WPCI allows both organizations to capture the high volume market segment without incurring any additional expenses.
"American Bio Medica is once again at the forefront of industry innovation with a complete program that meets significant demand from our customers and distributors," said ABMC President and CEO Stan Cipkowski. "By providing qualified professionals to conduct the tests, lab confirmations of positive screens, and Medical Review Officers to review the positive results, we are confident the program will dramatically increase our market share and positively impact our bottom line."
The national collection network encompasses quality control, chain of custody documentation, SAMHSA laboratory confirmation of positive screens, Medical Review Officer (MRO) review of laboratory positives, and summary reports. Since it is offered for a fixed per test charge, the service will enable companies to better budget their substance abuse testing initiatives.
American Bio Medica Corporation develops, manufactures and markets inexpensive, accurate, on-site drugs of abuse diagnostic kits and support services worldwide. The Company's global distributors target the workplace, clinical, rehabilitation, physicians, corrections, and educational markets. ABMC's Rapid Drug Screen is proven to correlate 100% with the standard laboratory screening test.
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risk and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, intellectual property rights, and other risks detailed from time to time in the Company's periodic report filed with the Securities and Exchange Commission.
CONTACT: American Bio Medica Corp.
Stan Cipkowski, President & CEO
Melissa Decker, Investor Relations Manager
Tel: 800/227-1243
Fax: 518/822-0391
Email: abmc@taconic.net
www.americanbiomedica.com |
